2023-12-01T14:16:12-06:00 2022-12-31 BDO USA 200 OTTAWA AVE NW STE 300 GRAND RAPIDS MI 49503 990 2022-01-01 352711268 Intrepid Alliance Inc C/O BROWNE CONSULTING GROUP % BROWNE CONSULTING GROUP INTR 7817572081 ONE BROADWAY Suite 14TH FL CAMBRIDGE MA 01242 JAMES BERGIN TREASURER 7817572081 2023-11-10 true JAMES BERGIN 999009999 Jacob Cook P01240455 6167747000 2023-11-10 2 2022 2023-04-26 12:10:37Z X JAMES ANDERSON ONE BROADWAY 14TH FL CAMBRIDGE MA 01242 1499980 false X INTREPIDALLIANCE.ORG X 2021 DE PROMOTE THE COMMON BUSINESS INTEREST OF ITS MEMBERS OF ADVANCING GLOBAL HEALTH SECURITY THROUGH PANDEMIC PREPAREDNESS EFFORTS. 8 8 0 0 0 0 0 0 500000 1499980 0 0 0 0 500000 1499980 0 0 0 0 0 134220 0 0 0 47600 102030 47600 236250 452400 1263730 500000 1648182 47600 29052 452400 1619130 X THE PRIMARY PURPOSE OF THE CORPORATION IS TO PROMOTE THE COMMON BUSINESS INTEREST OF ITS MEMBERS OF ADVANCING GLOBAL HEALTH SECURITY THROUGH PANDEMIC PREPAREDNESS EFFORTS. THE CORPORATION WILL PURSUE THIS PURPOSE BY PROMOTING THE DEVELOPMENT OF NEW TREATMENTS FOR EMERGING VIRAL PANDEMIC PATHOGENS THROUGH COORDINATED EARLY SCIENCE, POLICY AND ADVOCACY, STAKEHOLDER ENGAGEMENT THAT FACILITATES INFORMATION SHARING, AND ADVANCING AND CREATING EFFICIENCIES IN EARLY RESEARCH AND DEVELOPMENT AMONG ITS MEMBERS AND OTHERS IN THE ANTIVIRAL R&D ECOSYSTEM. IN THIS WAY THE CORPORATION AIMS TO SUPPORT THE 100 DAY MISSION, AN INTERNATIONAL EFFORT BY THE INTERNATIONAL PANDEMIC PREPAREDNESS SECRETARIAT(IPPS.ORG) "TO PREPARE AS MUCH AS POSSIBLE SO THAT WITHIN THE FIRST 100 DAYS A PANDEMIC THREAT IS IDENTIFIED AN INITIAL REGIMEN OF THERAPEUTICS" CAN BE MADE AVAILABLE BY RESEARCH ENTERPRISES THAT ARE SAFE, EFFECTIVE AND AFFORDABLE. false false BEYOND COVID-19, GLOBALIZATION, URBAN EXPANSION, AND EXPLOITATION OF NATURAL HABITATS SUGGEST HUMANITY WILL FACE NEW FORMS OF RESPIRATORY AND OTHER PATHOGENS THAT HOLD THE POTENTIAL TO CAUSE PANDEMICS. ORALLY AVAILABLE SMALL-MOLECULE ANTIVIRAL DRUGS FOR RAPID MOBILIZATION AND DISTRIBUTION ARE A CRITICAL TOOL TO PROTECT SOCIETIES FROM ANOTHER VIRAL PANDEMIC. UNLIKE SOME VACCINES AND ANTIBODIES, ANTIVIRAL THERAPIES MIGHT BE LESS PRONE TO THE IMPACT OF VIRUS GENETIC EVOLUTION, MAY BE EFFECTIVE AGAINST A BROAD RANGE OF VIRUSES, AND CAN CHANGE THE COURSE OF DISEASE EVEN AFTER INFECTION. MOST SMALL MOLECULE ANTIVIRALS CAN BE PRODUCED RAPIDLY AND COST-EFFECTIVELY AT A GLOBAL SCALE IN EXISTING FACILITIES, BUT THEY REQUIRE YEARS TO DISCOVER AND DEVELOP, SO IT IS CRITICAL TO PROMOTE AND SUPPORT RESEARCH, ADVOCACY, AND SCIENTIFIC INFORMATION SHARING ACROSS THE ACADEMIC BIOTECH AND PHARMACEUTICAL INDUSTRY. IN ORDER TO CREATE EFFICIENCIES IN THE R&D ECOSYSTEM, THE CORPORATION WILL COLLABORATE WITH PARTNERS IN OTHER SECTORS AND ITS MEMBERS IN EXPLORING REDUNDANCIES AND OPPORTUNITIES TO COLLABORATE FOR THE BENEFIT OF HUMANITY SUCH AS SHARING NEW RESEARCH FINDINGS, CREATING STANDARDS SUCH AS TARGET PRODUCT PROFILES, BENCHMARKING GLOBAL R&D EFFORTS AGAINST PATHOGENS OF PANDEMIC CONCERN AND CREATING A LISTING OF PROMISING LEAD PRODUCT CANDIDATES BY RESEARCHERS GLOBALLY. WE HOPE TO ACCELERATE THE COLLECTIVE UNDERSTANDING OF VIRAL TARGETS AND INCREASE THE LIKELIHOOD OF THE R&D ECOSYSTEM IN IDENTIFYING PROMISING LEADS. THE CORPORATION INTENDS TO FACILITATE FURTHER SCIENTIFIC INFORMATION SHARING BY DEVELOPING WHITE PAPERS ON RELEVANT TOPICS, PERFORMING A LANDSCAPE AND NEEDS ASSESSMENT ACROSS PUBLIC AND PRIVATE ANTIVIRAL RESEARCH SECTORS, AND PROVIDING KNOWLEDGE-SHARING OPPORTUNITIES THROUGH ORGANIZING MEETINGS AND SEMINARS. false false false true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true 1 0 true 0 false false false false false false false false X 8 8 false false false false true true false true true false false true true true true false false true false false X BROWNE CONSULTING GROUP 7817572081 ONE BROADWAY 14TH FL CAMBRIDGE MA 01242 NINA HILL INTERIM SECRETARIAT 40.0 0.0 X 134220 0 0 ELLIOTT LEVY PRESIDENT 1.0 0.0 X X 0 0 0 TOMAS CHILAR DIRECTOR 1.0 0.0 X 0 0 0 MARGARET CHU-MOYER DIRECTOR 1.0 0.0 X 0 0 0 RUXANDRA DRAGHIA-AKLI DIRECTOR 1.0 0.0 X 0 0 0 MICHELLE PARKS DIRECTOR 1.0 0.0 X 0 0 0 KUMAR SINGH SAIKATENDU DIRECTOR 1.0 0.0 X 0 0 0 SUJATA VAIDYANATHAN DIRECTOR 1.0 0.0 X 0 0 0 JOHN YOUNG DIRECTOR 1.0 0.0 X 0 0 0 134220 0 0 1 false false false 0 0 MEMBERSHIP DUES 621500 1499980 1499980 1499980 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1499980 1499980 0 0 0 0 134220 0 0 0 0 0 0 0 8504 0 0 0 0 0 0 1068 0 0 0 0 0 0 0 0 0 HR/RECRUITING 92458 236250 500000 1645787 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2395 0 0 0 0 0 0 0 0 0 0 0 0 500000 1648182 47600 29052 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 47600 29052 X 0 0 0 0 452400 1619130 452400 1619130 500000 1648182 1263730 -97000 X false false false false true false FORM 990, PART VI, SECTION A, LINE 6: THE ORGANIZATION HAS MEMBERS THAT ARE ENGAGED IN THE PRODUCTION AND/OR DEVELOPMENT OF PHARMACEUTICAL PRODUCTS. FORM 990, PART VI, SECTION A, LINE 7A: THE MEMBERS HAVE THE RIGHT TO VOTE ON THE ADMISSION OF NEW MEMBERS, THE APPOINTMENT OR ELECTION OF DIRECTORS, THE REMOVAL OF DIRECTORS AND THE ADOPTION, AMENDMENT, CHANGE OR REPEAL OF THE ORGANIZATION'S ORGANIZING DOCUMENTS. FORM 990, PART VI, SECTION B, LINE 11B: THE ORGANIZATION'S FORM 990 IS PROVIDED TO THE BOARD FOR REVIEW PRIOR TO FILING. Organization engaged accountant to file 2022 extension for Form 990. We filed the extension on May 15, 2023. Organization did not receive letter confirming that extension was filed and accepted. We are attaching a copy of the extension as well as the certified mail receipt for your records in order to attempt to prevent a penalty from being assessed which would then need to have an abatement request submitted. Please consider this request to review and confirm that the attached extension is on the organization's account and consider the tax return timely filed. Thank You Jacob Cook